基于欧洲利拉鲁肽真实世界试点研究结果修改药物利用研究方案
Amendment of a drug utilization study protocol based on results from a real-world pilot study of liraglutide use in Europe
Saxenda®(利拉鲁肽)在欧洲上市后6个月,一项在德国和意大利开展的真实世界试点研究显示,德国利拉鲁肽起始患者招募可行性较差且剂量相关数据质量不符合目的。基于该结果,后续药物利用研究方案进行了修改以提升监管决策所需真实世界数据的质量。试点共接触218个中心,最终纳入39例 Saxenda® 起始者和52例 Victoza® 起始者。
- Atheline Major-Pedersen ORCID: orcid.org/0000-0002-1755-630X1,
- Jens Aberle2,
- Paolo Sbraccia3,
- Naveen Rathor1 &
- …
- Anne Helene Olsen1
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Abstract
Economic and time constraints may incite researchers to avoid formalized pilot studies. Here, we report results of a pilot study that amended the ensuing drug utilization study (DUS) protocol, thus ascertaining fit-for-purpose data availability and quality, to better support regulatory decision-making. This retrospective, multicenter medical chart review in Germany and Italy, 6 months after Saxenda® (liraglutide 3.0 mg, a once-daily human glucagon-like peptide-1 analog for weight management) launch, ahead of a full DUS, collected patient data. The target study population included 100 initiators (25 Saxenda® and 25 Victoza® initiators in both Germany and Italy). Written informed consent was obtained before medical chart data extraction. Overall, 218 sites were contacted, with 39 Saxenda® initiators (33 in Italy; six in Germany) and 52 Victoza® initiators (31 in Italy; 21 in Germany). Patient records were obtained for all enrolled Saxenda® and Victoza® initiators in Italy and Germany; however, availability of individual study variables varied, with follow-up body weight showing the greatest degree of missingness among Saxenda® initiators. The pilot study indicated a poor enrollment feasibility of Saxenda® initiators in Germany and an unfit-for-purpose dose-related data quality. Based on these findings, refinements were implemented in the ensuing DUS protocol to improve the collection of fit-for-purpose real-world data for regulatory decision-making.
Acknowledgements
Editorial and formatting support was provided by OPEN Health Communications and funded by Novo Nordisk, in accordance with Good Publication Practice (GPP) guidelines (www.ismpp.org/gpp-2022). The authors thank Nic Birch Jørgensen and Dorthe Charlotte Skovgaard for their contributions to this manuscript. Novo Nordisk delegated all study operational oversight, including site contact, to a contract research organization, IQVIA.
Funding
Funded by Novo Nordisk A/S.
Author information
Authors and Affiliations
Global Safety, Novo Nordisk A/S, Vandtårnsvej 114, Søborg, 2860, Denmark
Atheline Major-Pedersen, Naveen Rathor & Anne Helene Olsen
Universitäres Adipositas Centrum, Hamburg, Germany
Jens Aberle
Department of Systems Medicine, University Tor Vergata, Rome, Italy
Paolo Sbraccia
Authors
- Atheline Major-Pedersen
- Jens Aberle
- Paolo Sbraccia
- Naveen Rathor
- Anne Helene Olsen
Corresponding author
Correspondence to Atheline Major-Pedersen.
Ethics declarations
Ethics approval and consent to participate
The study was conducted in accordance with good pharmacovigilance practice (GVP). Prior to study initiation, the protocol, patient information/informed consent form (ICF) and patient enrolment procedures were reviewed and approved by an independent ethics committee (IEC)/institutional review board (IRB). The IECs/IRBs were transparent in their functioning, independent of the researcher, the sponsor, and any other undue influence, and were duly qualified.
Consent for publication
Not applicable.
Competing interests
Dr Major-Pedersen, Dr Rathor, and Dr Helene Olsen are employees of Novo Nordisk. Dr Aberle has received honoraria for advisory boards and speakers’ bureaus from Eli Lilly and Novo Nordisk. Dr Sbraccia serves/served on scientific advisory boards and received honoraria or consulting fees from Bruno Farmaceutici, Eli Lilly, Novo Nordisk, and Pfizer.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Major-Pedersen, A., Aberle, J., Sbraccia, P. et al. Amendment of a drug utilization study protocol based on results from a real-world pilot study of liraglutide use in Europe. Sci Rep (2026). https://doi.org/10.1038/s41598-026-79385-2
Received: 18 July 2025
Accepted: 30 October 2026
Published: 18 November 2026
DOI: https://doi.org/10.1038/s41598-026-79385-2
Keywords
来源:Nature 健康护理主题 · nature.com